细胞分裂周期蛋白6与肿瘤发生发展关系的研究进展

doi:10.13481/j.1671-587X.20260327

摘要/Abstract

摘要：

细胞分裂周期蛋白6（CDC6）是与多种细胞活动相关的三磷酸腺苷酶（ATPase）（AAA+ATPase）家族中的一员，具有ATPase活性，在真核生物中高度保守。CDC6是前复制复合体（pre-RC）的关键组成部分，参与启动DNA复制。同时还参与调控S/M期细胞周期检查点，调节细胞有丝分裂。CDC6在多种恶性肿瘤中异常表达，被视为是一种癌基因，其表达失调会导致DNA复制异常并发生DNA损伤，进而影响肿瘤的发生发展。多种药物和调节因子被证实可以抑制CDC6的表达，阻止肿瘤细胞的生长。因此，CDC6是一个潜在的治疗靶点和预后监测标志物。现基于国内外对CDC6的研究成果，对CDC6蛋白的结构、抑制剂及其在胶质瘤、前列腺癌（PCa）、乳腺癌和其他多种肿瘤中的发生机制进行综述，为恶性肿瘤的治疗提供参考。

关键词: 细胞分裂周期蛋白6, 胶质瘤, 前列腺肿瘤, 乳腺肿瘤, 抑制剂, 治疗靶点

Abstract:

Cell division cycle protein 6 （CDC6） is a member of the adenosine triphosphatase （ATPase） associated with diverse cellular activities（AAA+ATPase） family associated with a variety of cellular activities， which possesses ATPase activity and is highly conserved in eukaryotes. CDC6 is a key component of the pre-replication complex （pre-RC） and participates in the initiation of DNA replication. Meanwhile， it is also involved in regulating the S/M cycle checkpoints and modulating cell mitosis. CDC6 is abnormally expressed in a variety of malignant tumors and regarded as an oncogene. Its dysregulated expression leads to abnormal DNA replication and DNA damage， thereby affecting the occurrence and development of tumors. Moreover， a variety of drugs and regulatory factors have been confirmed to be able to inhibit the expression of CDC6 and block the growth of tumor cells. Therefore， CDC6 is a potential therapeutic target and prognostic biomarker. Based on the domestic and international research achievements of CDC6， this paper reviewed the structure and inhibitors of CDC6 protein， as well as its pathogenesis in glioma， prostate cancer（PCa）， breast cancer and many other tumors， so as to provide references for the treatment of malignant tumors.

Key words: Cell division cycle protein 6, Glioma, Prostate neoplasms, Breast neoplasms, Inhibitor, Therapeutic target

中图分类号:

R730.2

张丽娜,孟哲思,巴隆,孟峻. 细胞分裂周期蛋白6与肿瘤发生发展关系的研究进展[J]. 吉林大学学报(医学版), 2026, 52(3): 847-853.

Lina ZHANG,Zhesi MENG,Long BA,Jun MENG. Research progress in relationship between cell division cycle protein 6 and occurrence and development of tumor[J]. Journal of Jilin University(Medicine Edition), 2026, 52(3): 847-853.

参考文献 50

[1]	LI C， ZHANG E D， YU R， et al. Comprehensive multi-omics analysis showed that CDC6 is a potential prognostic and immunotherapy biomarker for multiple cancer types including HCC ［J］. Transl Oncol， 2025， 53： 102314.
[2]	LEE I， KIM G S， BAE J S， et al. The DNA replication protein Cdc6 inhibits the microtubule-organizing activity of the centrosome［J］. J Biol Chem， 2017， 292（39）： 16267-16276.
[3]	COOK J G， CHASSE D A， NEVINS J R. The regulated association of Cdt1 with minichromosome maintenance proteins and Cdc6 in mammalian cells［J］. J Biol Chem， 2004， 279（10）： 9625-9633.
[4]	KIM Y H， BYUN Y J， KIM W T， et al. CDC6 mRNA expression is associated with the aggressiveness of prostate cancer［J］. J Korean Med Sci， 2018， 33（47）： e303.
[5]	JIANG W， WELLS N J， HUNTER T. Multistep regulation of DNA replication by Cdk phosphorylation of HsCdc6［J］. Proc Natl Acad Sci U S A， 1999， 96（11）： 6193-6198.
[6]	KAN Q M， JINNO S， YAMAMOTO H， et al. ATP-dependent activation of p21WAF1/CIP1-associated Cdk2 by Cdc6［J］. Proc Natl Acad Sci U S A， 2008， 105（12）： 4757-4762.
[7]	PETRAKIS T G， VOUGAS K， GORGOULIS V G. Cdc6： a multi-functional molecular switch with critical role in carcinogenesis［J］. Transcription， 2012， 3（3）： 124-129.
[8]	BLOW J J， GILLESPIE P J. Replication licensing and cancer： a fatal entanglement？［J］. Nat Rev Cancer， 2008， 8（10）： 799-806.
[9]	CHEN X F， CHEN J B， YU X B， et al. FOXM1 promotes malignant proliferation of esophageal squamous cell carcinoma through transcriptional activating CDC6［J］. DNA Cell Biol， 2022， 41（7）： 671-682.
[10]	PU D Y， XU Y K， YU H C， et al. Comprehensive pan-cancer analysis reveals CDC6 as a potential immunomodulatory agent and promising therapeutic target in pancreatic cancer［J］. Transl Cancer Res， 2024， 13（8）： 4096-4112.
[11]	PETERSEN B O， WAGENER C， MARINONI F， et al. Cell cycle- and cell growth-regulated proteolysis of mammalian CDC6 is dependent on APC-CDH1［J］. Genes Dev， 2000， 14（18）： 2330-2343.
[12]	SCHMIDT J M， YANG R， KUMAR A， et al. A mechanism of origin licensing control through autoinhibition of S. cerevisiae ORC·DNA·Cdc6［J］. Nat Commun， 2022， 13（1）： 1059.
[13]	OKAYAMA H. Cdc6： a trifunctional AAA+ ATPase that plays a central role in controlling the G（1）-S transition and cell survival［J］. J Biochem， 2012， 152（4）： 297-303.
[14]	CALZADA A， SACRISTÁN M， SÁNCHEZ E， et al. Cdc6 cooperates with Sic1 and Hct1 to inactivate mitotic cyclin-dependent kinases［J］. Nature， 2001， 412（6844）： 355-358.
[15]	MAHMOODI CHALBATANI G， GHARAGOUZLOO E， MALEKRAEISI M A， et al. The integrative multi-omics approach identifies the novel competing endogenous RNA （ceRNA） network in colorectal cancer［J］. Sci Rep， 2023， 13（1）： 19454.
[16]	SIDERIDOU M， ZAKOPOULOU R， EVANGELOU K， et al. Cdc6 expression represses E-cadherin transcription and activates adjacent replication origins［J］. J Cell Biol， 2011， 195（7）： 1123-1140.
[17]	KIM W Y， SHARPLESS N E. The regulation of INK4/ARF in cancer and aging［J］. Cell， 2006， 127（2）： 265-275.
[18]	MARTIN L， RAINEY M， SANTOCANALE C， et al. Hypoxic activation of ATR and the suppression of the initiation of DNA replication through cdc6 degradation［J］. Oncogene， 2012， 31（36）： 4076-4084.
[19]	HERMAND D， NURSE P. Cdc18 enforces long-term maintenance of the S phase checkpoint by anchoring the Rad3-Rad26 complex to chromatin［J］. Mol Cell， 2007， 26（4）： 553-563.
[20]	YOSHIDA K， SUGIMOTO N， IWAHORI S， et al. CDC6 interaction with ATR regulates activation of a replication checkpoint in higher eukaryotic cells［J］. J Cell Sci， 2010， 123（Pt 2）： 225-235.
[21]	CHEN S S， CHEN X L， XIE G E， et al. Cdc6 contributes to cisplatin-resistance by activation of ATR-Chk1 pathway in bladder cancer cells ［J］. Oncotarget， 2016， 7（26）： 40362-40376.
[22]	ZHANG N， ZHANG L J， QIU B S， et al. Correlation of volume transfer coefficient Ktrans with histopathologic grades of gliomas［J］. J Magn Reson Imaging， 2012， 36（2）： 355-363.
[23]	LI G Z， ZHAI Y， WANG Z， et al. Postoperative standard chemoradiotherapy benefits primary glioblastoma patients of all ages［J］. Cancer Med， 2020， 9（6）： 1955-1965.
[24]	ZHAO J S， JIANG Y， ZHANG H Y， et al. The SRSF1/circATP5B/miR-185-5p/HOXB5 feedback loop regulates the proliferation of glioma stem cells via the IL6-mediated JAK2/STAT3 signaling pathway［J］. J Exp Clin Cancer Res， 2021， 40（1）： 134.
[25]	ZHAO H， SUN H， FANG J， et al. CDC6 overexpression contributes to the malignant phenotype of glioma via IL6/JAK2/STAT3 signaling［J］. Am J Cancer Res， 2024， 14（7）： 3372-3387.
[26]	WANG F， ZHAO F， ZHANG L， et al. CDC6 is a prognostic biomarker and correlated with immune infiltrates in glioma［J］. Mol Cancer， 2022， 21（1）： 153.
[27]	LI S B， HE Y P， CHEN K X， et al. RSL3 drives ferroptosis through NF-κB pathway activation and GPX4 depletion in glioblastoma［J］. Oxid Med Cell Longev， 2021， 2021： 2915019.
[28]	NGUYEN-NIELSEN M， BORRE M. Diagnostic and therapeutic strategies for prostate cancer［J］. Semin Nucl Med， 2016， 46（6）： 484-490.
[29]	KARANTANOS T， CORN P G， THOMPSON T C. Prostate cancer progression after androgen deprivation therapy： mechanisms of castrate resistance and novel therapeutic approaches［J］. Oncogene， 2013， 32（49）： 5501-5511.
[30]	WANG Q B， LI W， LIU X S， et al. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth［J］. Mol Cell， 2007， 27（3）： 380-392.
[31]	JIN F， FONDELL J D. A novel androgen receptor-binding element modulates Cdc6 transcription in prostate cancer cells during cell-cycle progression［J］. Nucleic Acids Res， 2009， 37（14）： 4826-4838.
[32]	MYATT S S， LAM E W. The emerging roles of forkhead box （Fox） proteins in cancer［J］. Nat Rev Cancer， 2007， 7（11）： 847-859.
[33]	LIU Y H， GONG Z C， SUN L Q， et al. FOXM1 and androgen receptor co-regulate CDC6 gene transcription and DNA replication in prostate cancer cells［J］. Biochim Biophys Acta， 2014， 1839（4）： 297-305.
[34]	MOURKIOTI I， POLYZOU A， VEROUTIS D， et al. A GATA2-CDC6 axis modulates androgen receptor blockade-induced senescence in prostate cancer［J］. J Exp Clin Cancer Res， 2023， 42（1）： 187.
[35]	CYRUS-DAVID M， KING J， BEVERS T， et al. Validity assessment of the breast cancer risk reduction health belief scale［J］. Cancer， 2009， 115（21）： 4907-4916.
[36]	BÖMER M， PÉREZ-SALAMÓ I， FLORANCE H V， et al. Jasmonates induce Arabidopsis bioactivities selectively inhibiting the growth of breast cancer cells through CDC6 and mTOR［J］. New Phytol， 2021， 229（4）： 2120-2134.
[37]	KONG X L， DUAN Y， SANG Y T， et al. LncRNA-CDC6 promotes breast cancer progression and function as ceRNA to target CDC6 by sponging microRNA-215［J］. J Cell Physiol， 2019， 234（6）： 9105-9117.
[38]	MAHADEVAPPA R， NEVES H， YUEN S M， et al. The prognostic significance of Cdc6 and Cdt1 in breast cancer［J］. Sci Rep， 2017， 7（1）： 985.
[39]	FAGHIHLOO E， SADEGHIZADEH M， SHAHMAHMOODI S， et al. Editorial expression of concern： Cdc6 expression is induced by HPV16 E6 and E7 oncogenes and represses E-cadherin expression［J］. Cancer Gene Ther， 2020， 27（5）： 394.
[40]	ZHANG J H， HE Y L， ZHU R， et al. Deregulated expression of Cdc6 as BCR/ABL-dependent survival factor in chronic myeloid leukemia cells［J］. Tumour Biol， 2017， 39（6）： 1010428317713394.
[41]	ZHANG X， XIAO D K， WANG Z Y， et al. microRNA-26a/b regulate DNA replication licensing， tumorigenesis， and prognosis by targeting CDC6 in lung cancer［J］. Mol Cancer Res， 2014， 12（11）： 1535-1546.
[42]	YOUN Y， LEE J C， KIM J， et al. Cdc6 disruption leads to centrosome abnormalities and chromosome instability in pancreatic cancer cells［J］. Sci Rep， 2020， 10（1）： 16518.
[43]	CHEN S S， QU X M， WAN P， et al. Norcantharidin inhibits pre-replicative complexes assembly of HepG2 cells［J］. Am J Chin Med， 2013， 41（3）： 665-682.
[44]	VAISHAMPAYAN U. Systemic therapy of advanced urothelial cancer［J］. Curr Treat Options Oncol， 2009， 10（3/4）： 256-266.
[45]	SHI X H， CHEN S S， ZHANG Y J， et al. Norcantharidin inhibits the DDR of bladder cancer stem-like cells through cdc6 degradation［J］. Onco Targets Ther， 2019， 12： 4403-4413.
[46]	OJIMA I， KUMAR K， AWASTHI D， et al. Drug discovery targeting cell division proteins， microtubules and FtsZ［J］. Bioorg Med Chem， 2014， 22（18）： 5060-5077.
[47]	HE Y， YAN D Y， ZHENG D P， et al. Cell division cycle 6 promotes mitotic slippage and contributes to drug resistance in paclitaxel-treated cancer cells［J］. PLoS One， 2016， 11（9）： e0162633.
[48]	HUSSAIN M， FIZAZI K， SAAD F， et al. Enzalutamide in men with nonmetastatic， castration-resistant prostate cancer［J］. N Engl J Med， 2018， 378（26）： 2465-2474.
[49]	TAN C Y， HAGEN T. Destabilization of CDC6 upon DNA damage is dependent on neddylation but independent of Cullin E3 ligases［J］. Int J Biochem Cell Biol， 2013， 45（7）： 1489-1498.
[50]	KE Y， GUO W， HUANG S， et al. RYBP inhibits esophageal squamous cell carcinoma proliferation through downregulating CDC6 and CDC45 in G1-S phase transition process［J］. Life Sci， 2020， 250： 117578.